You are viewing the site in preview mode

Skip to main content

Advertisement

Table 2 characteristics of the study population

From: Systemic fluoroquinolone prescriptions for hospitalized children in Belgium, results of a multicenter retrospective drug utilization study

Age 5.23 (1.75–12.44) median, interquartile range
< 1 years: 26 (9.9%)
1–3 years: 65 (24.8%)
3–6 years: 43 (16.4%)
6–12 years: 54 (20.6%)
12–18 years: 74 (28.2%)
Weight 18,6 kg (11.3–38.7) median, interquartile range
BMIa 16.44 (15.00–18.76) median, interquartile range
Fraction overweight or obesea 1–3 years #: 0/20
3–6 years: 7/43
6–12 years: 5/54
12–18 years:11/74
Study center Ghent University Hospital: 158 (60.3%)
Universitair Ziekenhuis Brussel: 104 (39.7%)
Sex Male 144 (55%), female 118 (45%)
Comorbidity Malignancies: 53 (20.2%) of which hematologic: 39 (73.6%)
Cystic fibrosis: 14 (5.3%) Benign blood disorders and immune deficiencies: 14 (5.3%)
Neurologic disorder: 38 (14.5%)
Congenital Anomalies of the Kidneys and Urinary Tract: 18 (6.9%)
Inflammatory bowel disease: 7 (2.7%)
Heart defect: 3 (1.1%)
Transplant organ: 3 (1.1%)
Congenital hernia diaphragmatica: 1 (0.4%)
None: 111 (42.4%)
Department Academic pediatrics ward: 104 (39.7%)
Pediatric oncology: 53 (20.2%)
PICU: 105 (40.1%)
  1. aDefined as BMI exceeding respectively p85 or p95 for age and sex specific curves for Belgian children.
  2. #Starting for children of 2 years and older